- জেনেরিক নাম
- Acalabrutinib
- শক্তি
- 100 mg
- ডোজ ফর্ম
- Capsule
- প্রস্তুতকারক
- Everest Pharmaceuticals Ltd.
- থেরাপিউটিক ক্লাস
- Tyrosine Kinase Inhibitor
৳ ৯৮০ ৳ ১০০০.০০ ২% ছাড় প্রতি ইউনিট
দাম হালনাগাদ: ১৮ Nov ২০২৬
Acaluxen 100 mg Capsule একটি ক্যাপসুল ঔষধ, যার জেনেরিক নাম Acalabrutinib এবং শক্তি ১০০ mg। Acalabrutinib-এর অন্য ব্র্যান্ডগুলো এই পাতায় কম দাম থেকে সাজানো আছে, দাম তুলনা করতে পারবেন। Acaluxen-এর প্রতি ইউনিটের দাম ১০০০.০০ টাকা। এই ব্র্যান্ডের প্রস্তুতকারক Everest Pharmaceuticals Ltd। ঔষধটি Tyrosine Kinase Inhibitor শ্রেণির অন্তর্ভুক্ত। ডাক্তারের প্রেসক্রিপশন মেনে চলুন এবং অন্য ব্র্যান্ড খাওয়া যাবে কি না তা ফার্মাসিস্টের কাছ থেকে জেনে নিন।
Acaluxen is a brand of acalabrutinib, a tyrosine kinase inhibitor made by Everest Pharmaceuticals Ltd. It comes as 100 mg capsules. Acalabrutinib works by blocking a protein called BTK that helps some cancer cells grow and survive. It is used in adults for mantle cell lymphoma after at least one earlier treatment, and for chronic lymphocytic leukaemia or small lymphocytic lymphoma. Because it is a specialist cancer medicine, only a qualified doctor can decide whether it is right for a particular person. The dose, course and any changes are set by the doctor, not by the patient.
Acaluxen is used in adults to treat mantle cell lymphoma when at least one other treatment has already been given. It is also used for chronic lymphocytic leukaemia and small lymphocytic lymphoma. It belongs to a group of medicines called kinase inhibitors, which target specific proteins inside cancer cells. It is not a general-purpose medicine and should only be used under the care of a cancer specialist. Ask the doctor for details about how it fits into your treatment plan.
Acaluxen capsules are swallowed whole with water and should not be broken, opened or chewed. The doctor decides the dose and how long the course lasts, and may change the schedule based on how you respond and any side effects. Do not adjust the dose yourself. Tell your doctor about all other medicines you take, because some medicines can interact with acalabrutinib. If you miss a dose, ask your doctor or pharmacist what to do rather than guessing.
Common side effects include low red blood cell counts (anaemia), low white cell counts (neutropenia), low platelet counts, upper respiratory tract infection, headache, diarrhoea and pain in muscles or bones. Some people may have more serious problems such as infections, bleeding, heart rhythm changes or other cancers. Tell your doctor promptly about any unusual bleeding, fever, signs of infection, or a racing or irregular heartbeat. The doctor will arrange regular blood tests and monitor you during treatment.
Acaluxen can cause serious infections, bleeding, low blood counts and heart rhythm problems, so regular monitoring is needed. It may harm an unborn baby; pregnancy should be avoided during treatment, and effective contraception should be discussed with the doctor. It is not known whether acalabrutinib passes into breast milk, so breastfeeding should be discussed with the doctor. Before starting, tell your doctor if you are pregnant or breastfeeding, have liver problems, take other medicines, or have had bleeding or heart problems. The doctor will decide if it is safe for you.
Acaluxen contains acalabrutinib, a kinase inhibitor. It is used in adults for mantle cell lymphoma after at least one earlier treatment, and for chronic lymphocytic leukaemia or small lymphocytic lymphoma. Only a specialist doctor can decide if it is suitable for you.
Swallow the capsule whole with water; do not break, open or chew it. The doctor decides the dose, how often to take it and how long the course lasts, and may adjust it. Never change the dose yourself without speaking to your doctor.
Acaluxen may harm an unborn baby. There is no information on whether it passes into breast milk, so breastfeeding is not advised unless your doctor says otherwise. Tell your doctor if you are pregnant, planning pregnancy or breastfeeding.
The listed price is ৳ ১০০০.০০.
৳ ৯৮০ ৳ ১০০০.০০ ২% ছাড় প্রতি ইউনিট
দাম হালনাগাদ: ১৮ Nov ২০২৬
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Acaluxen is a kinase inhibitor indicated for the treatment of adult patients with:এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Acalabrutinib is a small-molecule inhibitor of BTK. Acalabrutinib and its active metabolite, ACP-5862, form a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B cell antigen receptor (BCR) and cytokine receptor pathways. In B cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. In nonclinical studies, acalabrutinib inhibited BTK-mediated activation of downstream signaling proteins CD86 and CD69 and inhibited malignant B-cell proliferation and tumor growth in mouse xenograft models.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
The recommended dose of Acalabrutinib is 100 mg taken orally approximately every twelve hours until disease progression or unacceptable toxicity. Advise patients to swallow capsule whole with water. Advise patients not to open, break or chew the capsules. Acalabrutinib may be taken with or without food. If a dose of Acalabrutinib is missed by more than 3 hours, it should be skipped and the next dose should be taken at its regularly scheduled time. Extra capsules of Acalabrutinib should not be taken to make up for a missed dose.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Effect of CYP3A Inhibitors on Acaluxen: Co-administration with a strong CYP3A inhibitor (200 mg Iitraconazole once daily for 5 days) increased the Acaluxen Cmax by 3.9-fold and AUC by 5.1-fold in healthy subjects. Physiologically based pharmacokinetic (PBPK) simulations with Acaluxen and moderate CYP3A inhibitors (erythromycin, fluconazole, diltiazem) showed that co-administration increased Acaluxen Cmax and AUC increased by 2- to almost 3-fold.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Most common adverse reactions (incidence ≥30%) were: anemia, neutropenia, upper respiratory tract infection, thrombocytopenia, headache, diarrhea, and musculoskeletal pain.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Pregnancy: Based on findings in animals, Acalabrutinib may cause fetal harm when administered to a pregnant woman. There are no available data in pregnant women to inform the drug-associated risk. In animal reproduction studies, administration of Acalabrutinib to pregnant rabbits during organogenesis resulted in reduced fetal growth at maternal exposures (AUC) approximately 4 times exposures in patients at the recommended dose of 100 mg twice daily. Advise pregnant women of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Hemorrhage: Serious hemorrhagic events, including fatal events, have occurred in the combined safety database of 612 patients with hematologic malignancies treated with Acaluxen monotherapy. Grade 3 or higher bleeding events, including gastrointestinal, intracranial, and epistaxis have been reported in 2% of patients. Overall, bleeding events including bruising and petechiae of any grade occurred in approximately 50% of patients with hematological malignancies. The mechanism for the bleeding events is not well understood. Acaluxen may further increase the risk of hemorrhage in patients receiving antiplatelet or anticoagulant therapies and patients should be monitored for signs of bleeding. Consider the benefit-risk of withholding Acaluxen for 3-7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Do not store above 30⁰C. Keep away from light and out of the reach of children.ঔষধের তথ্য শুধু জানার জন্য, এটি চিকিৎসা পরামর্শ নয়। সবসময় ডাক্তারের প্রেসক্রিপশন মানুন এবং ফার্মাসিস্টের সাথে কথা বলুন।